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Efavirenz, a non-nucleoside reverse transcriptase inhibitor, has been an important component of the
treatment of HIV infection for 10 years and has contributed signiﬁcantly to the evolution of highly
active antiretroviral therapy (HAART). The efﬁcacy of efavirenz has been established in numerous ran-
domized trials and observational studies in HAART-naive patients, including those with advanced
infection. In the ACTG A5142 study, efavirenz showed greater virological efﬁcacy than the boosted pro-
tease inhibitor (PI), lopinavir. Efavirenz is more effective as a third agent than unboosted PIs or the
nucleoside analogue abacavir. Some, but not all, studies have suggested that efavirenz (added to two
nucleoside reverse transcriptase inhibitors) is more effective than nevirapine. Virological and immuno-
logical responses achieved with efavirenz-based HAART have been maintained for 7 years. Dosing
convenience predicts adherence, and studies have demonstrated that patients can be switched from
PI-based therapy to simpliﬁed, once-daily efavirenz-based regimens without losing virological control.
The one-pill, once-daily formulation of efavirenz plus tenofovir and emtricitabine offers a particular
advantage in this regard. Efavirenz also retains a role after failure of a ﬁrst PI-based regimen. Efavirenz
is generally well tolerated: rash and neuropsychiatric disturbances are the most notable adverse
events. Neuropsychiatric disturbances generally develop early in treatment and they tend to resolve
with continued administration, but they are persistent and troubling in a minority of patients. Efavirenz
has less effect on plasma lipid proﬁles than some boosted PIs. Lipodystrophy can occur under treat-
ment with efavirenz but it may be reduced if the concurrent use of thymidine analogues is avoided.
Efavirenz resistance mutations (especially K103N) can be selected during long-term treatment,
underscoring the importance of good adherence. Recent data have conﬁrmed that efavirenz is a
cost-effective option for ﬁrst-line HAART. In light of these features, efavirenz retains a key role in HIV
treatment strategies and is the ﬁrst-line agent recommended in some guidelines.
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Introduction
The development and reﬁnement of highly active antiretroviral
therapy (HAART) during the last 10 years has dramatically
prolonged the survival of HIV-infected individuals.
1,2 In
comparison with earlier combination regimens, current options
are associated with greater viral suppression
3,4 and lower discon-
tinuation rates due to improved convenience and tolerability.
5
According to current guidelines, HAART regimens for initial
use should comprise two nucleoside reverse transcriptase
inhibitors (NRTIs) plus either a non-nucleoside reverse
transcriptase inhibitor (NNRTI) or a boosted protease inhibitor
(PI).
3,4,6,7
The timing of HAART initiation is a controversial issue inﬂu-
enced by the relative beneﬁt of treatment according to the
disease stage, the impact of the therapy itself on the patient’s
health and lifestyle, the need for long-term adherence and the
risk of developing resistance. Other considerations that generally
favour initiation of therapy include older age (the risk of
progression to AIDS is higher in older patients), high cardio-
vascular risk and the presence of co-morbidities such as
HIV-associated nephropathy. There is now a consensus that
HAART should be initiated when the CD4 cell count falls to
,350 cells/mm
3.
3,4,6,7 Accumulating evidence suggests that
starting HAART at higher CD4 cell counts (i.e. earlier in the
disease process) may further improve virological response,
immunological recovery and disease prognosis.
8 Thus, current
recommendations state that HAART initiation be considered in
some patients with CD4 counts of 350–500 cells/mm
3 if they
have risk factors for poor prognosis such as high viral
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cited.load (VL), rapidly declining CD4 cell count or hepatitis
co-infection.
3,4,6,7 The earlier commencement of HAART,
coupled with the longer survival of recipients, has increased the
duration of antiretroviral drug exposure and prompted greater
consideration of the long-term metabolic adverse effects of
regimens and the durability of their efﬁcacy.
Licensed in the EU in 1999, the NNRTI efavirenz has been
an important component of the treatment of HIV infection for
10 years and has contributed signiﬁcantly to the evolution of
HAART. Currently efavirenz is a recommended option for
initial therapy and is usually regarded as the preferred
NNRTI.
3,4,6,7 Indeed, the combination of efavirenz plus two
NRTIs is recommended as the regimen of choice for initial
therapy in the current UK guidelines.
3 This article reviews the
pharmacokinetics, long-term efﬁcacy, resistance development,
safety and cost-effectiveness of efavirenz.
Pharmacokinetics
Absorption
Peak efavirenz plasma concentrations are reached by 5 h follow-
ing single oral doses in uninfected volunteers.
9 The time to peak
plasma concentrations is  325 h and steady-state plasma con-
centrations of efavirenz are reached in 627d a y s .
9 The bioavail-
ability of a single 600 mg dose of efavirenz hard capsules in
uninfected volunteers is increased by 17%222% by food.
9
Efavirenz is highly bound ( 99.5%299.75%) to human plasma
proteins, predominantly albumin.
9,10
Biotransformation
Efavirenz is converted to inactive hydroxylated metabolites by the
cytochrome P450 system. CYP2B6 is one of the major isozymes
responsible for efavirenz metabolism.
11 Efavirenz plasma exposure
is increased in patients with the homozygous G516T genotype of
CYP2B6.
12,13 This is not associated with treatment failure,
12 but it
can lead to a higher rate of neuropsychiatric adverse events.
14–17
In this situation, dose reduction is feasible and maintains virologi-
cal suppression.
17 The G516T genotype is more common in
African Americans than in European Americans
16 and this has
been reported to cause greater efavirenz exposure, although there
is considerable overlap between racial/ethnic populations.
16,18 The
C1459T polymorphism has been reported not to affect efavirenz
exposure.
18 Other alleles of CYP2B6 may also inﬂuence efavirenz
metabolism.
19,20 Exposure to efavirenz is signiﬁcantly higher in
women than in men.
18
Elimination
Efavirenz has a terminal half-life of at least 52 h after single
doses and 40255 h after multiple doses.
9 Approximately
14%234% of a radiolabelled dose of efavirenz is recovered in
the urine and ,1% of the dose is excreted in urine as unchanged
efavirenz.
9 The half-life of efavirenz appears to be shorter
( 24 h) when it is given in combination with didanosine and
emtricitabine,
21 but this combination is effective and well toler-
ated in long-term therapy.
22
The long half-life of efavirenz makes it suitable for once-daily
dosing. The recommended dosage in adults is 600 mg once daily.
Genotypic testing for variants of the CYP2B6 allele could detect
individuals at increased risk of neuropsychiatric adverse events but
this is not routine practice. There is no recommendation to adjust
the dose of efavirenz according to race or sex.
Efﬁcacy
Treatment-naive patients
The efﬁcacy of efavirenz has been established in numerous trials
in HAART-naive patients. Studies have compared efavirenz
against PIs, other NNRTIs and triple NRTI regimens. In
addition, efavirenz has been used as the common ‘third agent’ in
evaluations of many NRTI combinations.
Comparison with PIs
The early randomized, open-label DMP 266-006 study showed
that efavirenz was superior to unboosted indinavir when both
were administered over 48 weeks with an NRTI backbone of
zidovudine plus lamivudine.
23 See Table 1.
In other studies, efavirenz was as effective as unboosted ata-
zanavir
38 and more effective than unboosted nelﬁnavir
24,39 when
all were combined with two NRTIs (Table 1).
More recently, the AIDS Clinical Trial Group (ACTG)
performed a landmark comparison of efavirenz versus ritonavir-
boosted lopinavir.
25 ACTG A5142 was a randomized, open-label,
96 week study of efavirenz versus boosted lopinavir—each admi-
nistered with lamivudine plus zidovudine, stavudine or tenofo-
vir—and efavirenz plus boosted lopinavir (an NRTI-sparing
regimen). The primary endpoint analysis was the time to virolo-
gical failure, deﬁned as a lack of VL suppression by 1 log10 HIV
RNA copies/mL or rebound before week 32, or a lack of VL sup-
pression to ,200 copies/mL or rebound after week 32. The efa-
virenz group showed a signiﬁcantly longer time to this endpoint
with a relative hazard ratio (HR) of 0.63 [95% conﬁdence inter-
val (CI) 0.45–0.87; P¼0.006] (Figure 1).
25 The time to regimen
failure (deﬁned as virological failure or toxicity-related discon-
tinuation of any component of the randomized regimen) also
showed a beneﬁt for efavirenz over boosted lopinavir (HR 0.75;
95% CI 0.57–0.98; P¼0.03), although this failed to reach
the signiﬁcance threshold adjusted for multiple comparisons
(P¼0.014). In terms of virological response, signiﬁcantly
more patients treated with efavirenz-based therapy achieved a VL
of ,200 copies/mL or ,50 copies/mL at 96 weeks than did
boosted lopinavir-treated patients, although the median increase
in CD4 cell count was smallest in the efavirenz arm (Table 1). At
96 weeks, recurrent or new AIDS-deﬁning conditions occurred in
4% of patients receiving efavirenz-based therapy versus 6% of
those in the other arms.
Another, smaller study showed efavirenz to be superior to
boosted lopinavir in patients with low CD4 cell counts, as dis-
cussed below.
26 Observational cohort studies have also found
that efavirenz has virological efﬁcacy at least as high and
durable as boosted lopinavir (and in some studies more so),
including in patients with advanced disease. These studies
include the Swiss HIV Cohort,
40 EfaVIP 2,
41 MASTER,
42
TEQUILA,
43 SUSKA
44 and Antiretroviral Therapy Cohort
Collaboration (ART-CC)
45 studies (Table 2).
The retrospective SUSKA study showed no difference between
efavirenz (n¼1159) and boosted lopinavir (n¼391) in the
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911Table 1. Randomized studies that compared efavirenz with PIs, other NNRTIs or abacavir as third agents or which used efavirenz in evaluations of NRTI combinations in
HIV-infected, treatment-naive patients (ITT analyses)
Baseline
VL CD4 Percentage with VL:
Trial Design Treatment n
(copies/
mL)
(cells/
mm
3) Time ,400 copies/mL ,50 copies/mL
Time to virological failure,
HR (95% CI)
CD4 increase
(cells/mm
3)
EFV vs PI
DMP 266-006
23 OL patients with  100
CD4 cells/mm
3
EFVþZDVþ3TC 361 4.70 366.4 48 weeks 72.5 (P 0.05 vs IDV) 66.6 (P 0.05 vs IDV) NR 200
IDVþZDVþ3TC 357 4.70 388.5 52.1 47.2 183
EFVþIDV 356 4.71 379.0 62.0 (P 0.05 vs IDV;
P 0.05 vs CD4 ,100)
56.1 (P 0.05 vs IDV;
P 0.05 vs CD4 ,100)
183
patients with ,100
CD4 cells/mm
3
EFVþZDVþ3TC 46 5.28 64.5 48 weeks 69.8 58.1 NR 184
IDVþZDVþ3TC 47 5.23 61.3 50.0 40.9 177
EFVþIDV 49 5.43 65.6 38.1 23.8 118
Maggiolo
24 OL EFVþddIþ3TC 34 5.21 184 52 weeks NR 77.4 NR 194
EFVþZDV/3TC 34 5.22 175 77.4 183
NFVþZDV/3TC 34 5.16 169 50.0 (P¼0.02 vs EFV) 165
ACTG A5142
25 OL EFVþ2 NRTIs 250 4.8
a 195
a 96 weeks NR 89 (P¼0.003 vs LPV/r) EFV vs LPV/r: 0.63
(0.45–0.87) (P¼0.006)
230
a
LPV/rþ2 NRTIs 253 4.8 190 77 EFV vs EFVþLPV/r: 0.86
(0.61–1.21)
287 (P,0.01
vs EFV)
EFVþLPV/r 250 4.9 189 83 273 (P,0.01
vs EFV)
Sierra-Madero
26 OL EFVþZDVþ3TC 95 NR 64
a 48 weeks 73 70 (P¼0.0141) NR 156.9
LPV/rþZDVþ3TC 94 NR 52 65 54 166.9
EFV vs NNRTI
2NN
27 OL EFVþ3TCþd4T 400 4.7
a 190
a 48 weeks NR 70.0 NR 160
a
NVP QD 220 4.7 200 70.0 170
NVP BID 387 4.7 170 65.4 160
EFVþNVP 209 4.7 190 62.7 150
FIRST
28 NR EFVþ2 NRTIs 111 5.0
a 181
a 5 years NR
b NR NR
b 172
NVPþ2 NRTIs 117 5.1 196 NR 153
Continued
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2Table 1. Continued
Baseline
VL CD4 Percentage with VL:
Trial Design Treatment n
(copies/
mL)
(cells/
mm
3) Time ,400 copies/mL ,50 copies/mL
Time to virological failure,
HR (95% CI)
CD4 increase
(cells/mm
3)
EFV vs triple NRTIs
ACTG A5095
29 DB EFVþZDV/
3TC/+ABC
765 4.86 242 48 weeks NR 83 NR
c 173
ABCþZDV/3TC 382 4.85 234 61 174
Evaluations of NRTIs
EPV20001
30 DB EFVþZDVþ3TC
QD
278 4.64
a 340
a 48 weeks 59 64 NR 144
a
EFVþZDVþ3TC
BID
276 4.69 386 61 63 146
CNA30021
31 DB EFVþ3TCþABC
QD
384 4.91
a 264
a 48 weeks NR 66 NR 188
a
EFVþ3TCþABC
BID
386 4.87 259 68 200
CNA30024
32 DB EFVþ3TCþABC 324 4.81
a 267
a 48 weeks 74 70 NR 209
a
325 4.81 258 71 69 155 (P¼0.005)
ACTG A5095
33 DB EFVþZDV/3TC 382 4.87 238 192 weeks NR  84 3 vs 4 drugs: 0.95
(0.69–1.33)
 310
EFVþZDV/3TC/
ABC
383 4.84 242 NR  88  275
GS903
34 DB EFVþ3TCþTDF 299 4.91 276 144 weeks 70.6 67.9 NR 263
EFVþ3TCþd4T 301 4.91 283 64.1 62.5 283
FTC-301A
35 DB EFVþddIþFTC 268 4.8 312 60 weeks 79 76 NR 153 (48 w)
EFVþddIþd4T 285 4.8 324 63 (P,0.001) 54 (P,0.001) 120 (48 w)
(P¼0.02)
GS934
36,37 OL EFVþTDFþFTC 244 5.0
a 233
a 144 weeks 64 71 NR 312
a
EFVþZDV/3TC 243 5.0 241 56 (P¼0.08) 58 (P¼0.004) 271
ABC, abacavir; CI, conﬁdence interval; DB, double blind; EFV, efavirenz; FTC, emtricitabine; HR, hazard ratio; NNRTI, non-nucleoside reverse transcriptase inhibitor; NR, not reported; NRTI, nucleoside
reverse transcriptase inhibitor; OL, open-label; TDF, tenofovir; VL, viral load; vs, versus; ddI, didanosine; 3TC, lamivudine; d4T, stavudine; LPV/r, lopinavir/ritonavir; ZDV, zidovudine; IDV, indinavir;
NFV, nelﬁnavir; NVP, nevirapine; QD, once daily; BID, twice daily.
Note: / indicates co-formulated drugs; þ indicates components administered separately;   indicates value estimated from a graph.
aMedians; other continuous data are means.
bThere was no signiﬁcant difference between groups in the proportion of patients who fulﬁlled the primary composite endpoint (VL 50 copies/mL at or after 8 months or death: HR 0.92; 95% CI
0.69–1.23), or in either component of this composite. However, patients randomized to EFV were signiﬁcantly less likely to experience virological failure associated with NNRTI resistance (HR 0.65; 95%
CI 0.41–1.01; P¼0.05), NRTI resistance (HR 0.20; 95% CI 0.08–0.52; P,0.01) or any resistance (HR 0.60; 95% CI 0.39–0.93; P¼0.02).
cThe time to virological failure was signiﬁcantly shorter with ABC-based therapy compared with EFV-based therapy (P,0.001).
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3adjusted HRs for virological failure (0.93; 95% CI 0.77–1.12;
P¼0.43), CD4 recovery (1.11; 95% CI 0.95–1.30; P¼0.19) and
clinical progression (0.71; 95% CI 0.39–1.31; P¼0.27).
44
However, recipients of boosted lopinavir were approximately
twice as likely to discontinue treatment for any reason or for tox-
icity (HR 2.10; 95% CI 1.40–3.15; P¼0.0003). The ART-CC
study assessed virological failure (VL of .500 copies/mL) at
24 weeks and clinical outcomes within 2 years following the
initiation of various third agents (each in combination with lami-
vudine and zidovudine) in a large cohort of 13546 patients from
Europe, Canada and the USA.
45 According to multivariate analy-
sis, virological failure was less likely to occur with efavirenz than
with any other third agent evaluated. Compared with efavirenz the
adjusted odds ratio (OR) for the risk of failure ranged from 3.20
(95% CI 2.74–3.74) with nelﬁnavir to 1.32 (95% CI 1.12–1.57)
with boosted lopinavir. The incidence of clinical AIDS events or
death did not differ between efavirenz and these PIs; however,
each regimen was associated with a 2 year AIDS-free survival rate
of  95% (Figure 2).
45
Comparison with other NNRTIs
Few randomized studies have compared efavirenz with nevira-
pine, the only other NNRTI currently licensed for use as ﬁrst-
line therapy (Table 1). In the 2NN study, nevirapine did not
meet the criteria for non-inferiority as compared with
efavirenz.
27
Recently, pertinent results were reported from the FIRST
study, in which patients were randomized to one of three strat-
egies: NNRTI plus NRTIs, PI plus NRTIs or a combination
of all three classes (NNRTI plus PI plus NRTI). Patients
randomized to receive an NNRTI plus NRTIs or the three-class
strategy could choose their NNRTI or accept additional ran-
domization to efavirenz or nevirapine.
28 Among patients ran-
domized in this NNRTI substudy (n¼228), there was no
signiﬁcant difference between the efavirenz and nevirapine arms
in the primary endpoint of the proportion of patients with a VL
of  50 copies/mL (at or after 8 months) or death (HR 0.92; 95%
CI 0.69–1.23). Similarly, there was no signiﬁcant difference in
rates of overall virological suppression or failure (although sig-
niﬁcant beneﬁts for failure associated with resistance were
reported for efavirenz, as discussed below), or in CD4 cell count
recovery (Table 1). A similar pattern of results was observed in
the total cohort comprising patients randomized to an NNRTI
and those who had chosen their NNRTI. Randomized patients
treated with efavirenz showed a signiﬁcantly higher adjusted rate
of disease progression events or death (HR 2.19; 95% CI
1.26–3.81; P¼0.01), but the combined cohort did not show this
ﬁnding and the substudy was not powered to evaluate events.
Large observational studies have reported superior virologi-
cal, immunological and clinical outcomes with efavirenz over
nevirapine
45,46 (Table 2). In the ART-CC cohort, nevirapine
initiation was associated with an adjusted OR for 24 week viro-
logical failure of 1.87 (95% CI 1.58–2.22) versus efavirenz.
45
Furthermore, nevirapine use was associated with a signiﬁcantly
higher incidence of AIDS events or death over 2 years, com-
pared with efavirenz (Figure 2).
Comparison with triple NRTIs
The use of the triple NRTI combination of zidovudine plus lami-
vudine and abacavir in the randomized, double-blind ACTG
A5095 study was halted when an interim analysis at 32 weeks
revealed that virological failure had occurred in almost twice as
many of the patients treated with the triple NRTI regimen (21%)
as in those treated with efavirenz plus either two or three NRTIs
(11%; P,0.001).
29 Efavirenz-based therapy maintained high
levels of efﬁcacy over 3 years, with abacavir adding no further
beneﬁt over efavirenz plus lamivudine and zidovudine.
33,47
In the observational ART-CC cohort, the use of abacavir
rather than efavirenz as the third agent (added to zidovudine
plus lamivudine) was more likely to be associated with virologi-
cal failure (adjusted OR 2.13; 95% CI 1.82–2.50) and with the
occurrence of an AIDS-deﬁning event or death over 2 years
(Figure 2).
45
Comparisons with new classes of antiretroviral agent
CCR5 antagonists. Maraviroc is a CCR5 antagonist that inhibits
virus/cell binding via inhibition of the co-receptor target CCR5
on the surface of host CD4 cells. Maraviroc is not active against
the CXCR4 co-receptor and an HIV tropism test, e.g. a
TroﬁleTM assay, must be performed before treatment to ensure
that patients are infected with the R5-using strain of the HIV-1
virus. The randomized, double-blind MERIT study compared
the efﬁcacy and tolerability of maraviroc (n¼360) with efavir-
enz (n¼361) in treatment-naive patients infected with R5
HIV-1, with both treatment groups also receiving Combivir
(zidovudine/lamivudine).
48 At 48 weeks, maraviroc did not show
non-inferiority (margin 10%) compared with efavirenz for the
primary endpoint of a VL ,50 copies/mL (65.3% versus 69.3%;
lower limit of one-sided 97.5% CI –10.9%). In addition, more
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Figure 1. Time to virological failure in patients treated with efavirenz (upper
line), boosted lopinavir (middle line), each in combination with two NRTIs,
or efavirenz plus boosted lopinavir (lower line), the NRTI-sparing regimen, in
the overall population in the AIDS Clinical Trial Group A5142 study.
Reproduced with permission from the New England Journal of Medicine.
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914Table 2. Observational cohort studies of efavirenz-based therapy (ITT analyses)
Baseline (median)
Trial (reference) Design Treatment n
log10 VL
(copies/mL)
CD4
(cells/mm
3) VF, HR (95% CI)
a
Time to treatment
failure, HR (95% CI)
VL,50 copies/mL
a,H R
(95% CI) or OR (95% CI)
CD4 recovery
a,H R
(95% CI)
EFV versus PI
Swiss HIV
Cohort
40
prospective EFVþ2 NRTIs 89 4.71 216 1.66 (1.11–2.49)
b 1.10 (0.80–1.52)
c
NFV or IDV or IDV/r
or SQV/rþ2 NRTIs
183 4.81 165 1
b 1
EfaVIP 2
41 retrospective EFVþ2 NRTIs 92 5.54 34 1
b 11
(advanced
disease)
NFV or IDV or RTV or
IDV/r or SQV/rþ2
NRTIs
218 5.40 38 4.91 (1.77–13.63)
b 2.19 (1.23–3.89)
d 0.80 (0.57–1.12)
e
MASTER
42 retrospective
longitudinal
EFVþ2 NRTIs 348 4.8
e 215
f 1
g
LPV/rþ2 NRTIs 124 4.9
e 176
f 0.40 (0.33–0.89)
g
TEQUILA
43 retrospective EFVþ2 NRTIs 665 5.26 37 1 1
(advanced
disease)
LPV/rþ2 NRTIs 495 5.30 35 1.19 (0.97–1.45)
h 1.17 (0.98–1.40)
i
SUSKA
44 retrospective
longitudinal
EFVþ2 NRTIs 1159 5.03 187 0.93 (0.77–1.12)
b 1.11 (0.95–1.30)
j
LPV/r 391 5.16 120 1
b 1
Evaluation of
third drug
ART-CC
45 EFVþZDVþ3TC 3788 4.9 207 1
g,k
NVPþZDVþ3TC 2151 4.7 260 1.87 (1.58–2.22)
g,k
LPV/rþZDVþ3TC 2875 5.1 150 1.32 (1.12–1.57)
g,k
NFVþZDVþ3TC 2217 4.8 214 3.20 (2.74–3.74)
g,k
ABCþZDVþ3TC 2515 4.7 251 2.13 (1.82–2.50)
g,k
ABC, abacavir; EFV, efavirenz; HR, hazard ratio; LPV, lopinavir; NFV, nelﬁnavir; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; OR, odds ratio; VF, virological failure; VL, viral load;
/r, ritonavir-boosted; 3TC, lamivudine; ZDV, zidovudine; IDV, indinavir; RTV, ritonavir; SQV, saquinavir.
Note: þ indicates components administered separately.
aMultivariate analysis unless stated otherwise.
bHazard ratio (95% CI).
cIncrease in CD4 count .50 cells/mm
3.
dTreatment failure deﬁned as: not achieving a VL of ,400 copies/mL or having an increase above limit of quantiﬁcation in two consecutive determinations after initial viral suppression; death; opportunistic
infections; therapy discontinuations; or lost to follow-up.
eProbability of reaching a CD4 count of .200 cells/mm
3.
fMean values.
gOdds ratio (95% CI).
hTreatment failure deﬁned as VF, death, opportunistic infection or treatment discontinuation.
iTime to CD4 count  200 cells/mm
3 in patients who did not experience VF.
jCD4 recovery deﬁned as .100 cells/mm
3 gain from baseline.
kVF deﬁned as a VL of .500 copies/mL at 24 weeks.
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5patients discontinued in the maraviroc compared with the efavir-
enz arm due to lack of efﬁcacy (11.9% versus 4.2%). However,
the mean change from baseline in CD4 cell count was greater
for patients receiving maraviroc than efavirenz (þ170 versus
þ144 cells/mm
3), and fewer patients experienced grade 3/4
adverse events in the maraviroc than in the efavirenz arm. A
recent re-analysis of the MERIT study found that maraviroc was
non-inferior to efavirenz for a VL of ,50 copies/mL if 15%
(106/721) of patients originally classiﬁed as R5 HIV-1, but
determined to have non-R5 HIV-1 using a more sensitive
TroﬁleTM assay, were excluded.
49
A Phase II dose-ﬁnding study of the CCR5 antagonist vicri-
viroc was discontinued because of a higher incidence of virolo-
gical failure among patients randomized to vicriviroc 25 or
50 mg twice daily than with efavirenz-based therapy.
50
Integrase inhibitors. Raltegravir is an integrase inhibitor which,
following promising results in patients with highly resistant
HIV,
51,52 was compared with efavirenz in treatment-naive
patients in the 004 and STARTMRK studies. The 004 study
compared the efﬁcacy and tolerability of raltegravir (n¼160)
against efavirenz (n¼38), both combined with tenofovir and
lamivudine.
53,54 For the ﬁrst 48 weeks patients receiving ralte-
gravir were randomized to doses of 100, 200, 400 or 600 mg
twice daily; all patients randomized to efavirenz received
600 mg once daily. At weeks 2, 4 and 8, more patients in each
raltegravir dose group reached VL ,50 copies/mL than those
receiving efavirenz.
53 These differences diminished with time;
by week 24 (the primary endpoint) and week 48 (the secondary
endpoint)  85% of patients reached VL ,50 copies/mL in each
treatment group. After 48 weeks, all raltegravir patients were
given 400 mg twice daily and were analysed as a single group.
At 96 weeks, the raltegravir and efavirenz groups exhibited
similar rates of viral suppression, with 83% and 84% of patients,
respectively, achieving VL ,50 copies/mL by intent-to-treat
(ITT) analysis.
54 Increases in CD4 cell count were also similar
for raltegravir and efavirenz (þ221 versus þ232 cells/mm
3,
respectively). Raltegravir was generally well tolerated, with
drug-related adverse events less frequent in the raltegravir arm
than in the efavirenz arm (51% versus 74%, respectively).
Raltegravir was more lipid-neutral than efavirenz with respect to
total cholesterol, low-density lipoprotein-cholesterol and trigly-
cerides.
53 The STARTMRK study reported 48 week data for
treatment-naive patients (n¼563) randomized to receive ralte-
gravir or efavirenz, both combined with tenofovir and emtricita-
bine.
55 At week 48, 86% of patients treated with raltegravir
(n¼281) and 82% with efavirenz (n¼283) achieved a VL of
,50 copies/mL, the primary study endpoint (P,0.001 for non-
inferiority; non-completer¼failure analysis), with the authors
stating that raltegravir was non-inferior to efavirenz. Patients in
the raltegravir arm had greater increases in CD4 cell count than
those in the efavirenz arm (þ189 versus þ163 cells/mm
3).
Raltegravir was generally well tolerated, with drug-related
adverse events signiﬁcantly less frequent in the raltegravir arm
than in the efavirenz arm (44% versus 77%; P¼0.001).
Another integrase inhibitor, elvitegravir, reduces VL in
treatment-experienced patients, but its effectiveness appears to
depend on active background therapy.
56 Elvitegravir has not
been compared directly with efavirenz.
Novel NNRTIs. Novel NNRTIs, including rilpivirine (TMC278)
and etravirine (TMC125), are under development. A dose-
ranging study compared 25, 75 or 150 mg of rilpivirine once
daily with 600 mg of efavirenz once daily (each added to two
NRTIs) in 368 treatment-naive patients.
57 The primary endpoint
was the proportion of patients with a VL of ,50 copies/mL at
48 weeks, which was reached by 80%, 80% and 77% of patients
treated with rilpivirine 25, 75 and 150 mg, respectively, versus
81% of those receiving efavirenz. Both treatments were gener-
ally well tolerated; rash and nervous system disorders were less
common with rilpivirine than with efavirenz. As discussed
below, clinical trials indicate that etravirine is effective and gen-
erally well tolerated in patients with HIV resistant to efavirenz
or nevirapine. A trial of 400 mg etravirine once daily versus
600 mg efavirenz once daily (each added to two NRTIs) in
treatment-naive patients is in progress.
58
Conclusions. At present there is no evidence that CCR5 antag-
onists, integrase inhibitors or novel NNRTIs are more effective
than efavirenz in treatment-naive patients, but further studies are
in progress. These new agents are generally well tolerated and
may have an important role after the failure of initial therapy.
Efavirenz in studies of NRTIs
Many studies comparing different NRTI combinations have used
efavirenz as the common third agent.
31,32,34,35,37 In the Gilead
Sciences (GS) 903 study, efavirenz-based regimens containing
lamivudine plus either tenofovir or stavudine were similarly
effective over 144 weeks of double-blind, randomized therapy
(Table 1).
34 Following a further 144 weeks of open-label
treatment (total 288 weeks), 71 of 86 (83%) patients originally
randomized to efavirenz plus tenofovir and lamivudine had a
VL of ,400 copies/mL and 69/86 (80%) had a VL of
,50 copies/mL.
59 Data conﬁrming the maintenance of
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Figure 2. Estimated AIDS-free survival among 13546 antiretroviral-naive
HIV-infected patients in the Antiretroviral Therapy Cohort Collaboration
study initiating antiretroviral therapy with zidovudine plus lamivudine
stratiﬁed by the third drug in their regimen (2000–2005). Survival curves are
estimated from a Weibull model with follow-up censored at 2 years, with
covariates set at the average value across the population of patients and for
the cohort with median survival. Efavirenz, continuous line; nevirapine, long
dashed line; boosted lopinavir, widely spaced dashed line; nelﬁnavir, short
dashed line; abacavir, dot plus dashed line. Corresponding adjusted HRs for
the composite of incident AIDS event or death, compared with efavirenz,
were: nevirapine, 1.20 (95% CI 0.95–1.50); boosted lopinavir, 1.08 (95% CI
0.89–1.32); nelﬁnavir, 0.95 (95% CI 0.77–1.18); and abacavir, 1.16 (95%
CI 0.92–1.45). Reproduced with permission from Mugavero et al.
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916virological and immunological responses at 7 years are available
in abstract form.
60 Following the randomized phase of GS903,
patients switched from stavudine to tenofovir (plus efavirenz
and lamivudine) also showed maintained virological suppression
and continued CD4 cell increases over 144 weeks.
61
In the GS934 study, the combination of efavirenz plus tenofo-
vir and emtricitabine proved superior to efavirenz plus lamivu-
dine and zidovudine for VL suppression and CD4 cell count
recovery up to 144 weeks (Table 1).
36,37,62 At 144 weeks, signiﬁ-
cantly more patients in the tenofovir/emtricitabine arm had a VL
of ,400 copies/mL (71% versus 58% on zidovudine/lamivu-
dine; P¼0.004). There were also trends favouring tenofovir/
emtricitabine for virological suppression to ,50 copies/mL (64
versus 56%; P¼0.08) and for the increase in CD4 cell count
(312 versus 271 cells/mm
3; P¼0.09).
Bartlett et al.
63 systematically reviewed the results of seven
trials that evaluated various NRTI regimens in combination with
efavirenz in terms of the time to loss of virological response
over 48 weeks (n¼3807 patients). Response rates were
65%284% for VL ,400 copies/mL and 61%280% for a VL of
,50 copies/mL, with regimens containing emtricitabine plus
tenofovir, didanosine or stavudine showing the best efﬁcacy
(Figure 3).
63 Virological failure occurred in 2%–8% of patients.
Treatment-experienced patients
Treatment simpliﬁcation
Adherence is a major predictor of the success of HAART,
64,65
with higher adherence rates leading to a lower risk of viral
rebound and resistance development.
66 The complexity of the
treatment regimen is an important barrier to good adherence
65,67
and patients generally prefer the simplicity of once-daily regi-
mens.
68,69 The use of once-daily agents and the co-formulation
of multiple antiretrovirals in ﬁxed-dose combinations have
simpliﬁed HAART regimens in recent years. As well as provid-
ing simpliﬁed initial HAART regimens, these approaches have
been used in switch strategies to improve convenience for
patients stabilized on more complicated regimens.
In the GS934 study, patients who had received 96 weeks
of treatment with efavirenz plus emtricitabine and tenofovir
were switched to efavirenz plus a ﬁxed-dose combination of
tenofovir/emtricitabine and continued to show high rates of
virological suppression.
37 In the uncontrolled COMET study,
virological suppression was also maintained when stable patients
(VL,400 copies/mL) on efavirenz plus twice-daily zidovudine
plus lamivudine had their NRTIs switched to once-daily ﬁxed-
dose tenofovir/emtricitabine.
70 Of 402 patients, only 2% discon-
tinued owing to adverse events and ,1% discontinued for viro-
logical failure. At 24 weeks, 87% of patients had a VL of
,400 copies/mL and 74% (versus 71% at baseline) had a VL of
,50 copies/mL. Following the switch, patients reported
increased satisfaction with treatment, fewer were bothered by
adverse events and adherence rates were improved (as measured
by the proportion who took  95% of doses). In the open-label
Simpliﬁcation With Easier Emtricitabine and Tenofovir
(SWEET) study, patients who were stabilized on efavirenz plus
ﬁxed-dose lamivudine/zidovudine (n¼250) were randomized to
remain on this regimen or to switch to ﬁxed-dose efavirenz plus
ﬁxed-dose tenofovir/emtricitabine.
71 At 48 weeks, the two arms
showed similar virological responses, with 88% of the switch
group and 85% of the continuation group achieving a VL of
,50 copies/mL. Discontinuation rates because of adverse events
were 3% and 5%, respectively. These data indicate that patients
can be switched from PI-based HAART to simpliﬁed efavirenz-
based regimens without loss of virological control.
The introduction of Atripla
w, a single-pill once-daily, ﬁxed-dose
formulation of efavirenz plus tenofovir and emtricitabine, has
further reduced the pill burden of HAART. The Phase IV, open-
label AI266073 study evaluated the effect of switching patients
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Figure 3. Virological response using the time to loss of virological response rate (TLOVR) for HIV RNA ,50 and ,400 copies/mL thresholds at week 48
by study arm. The NRTI combination for each study is identiﬁed on the bars and the number of subjects in each arm is listed. The diamond shape indicates
the TLOVR response rate at HIV RNA ,50 copies/mL. ABC, abacavir; BID, twice daily; FTC, emtricitabine; QD, once daily; TDF, tenofovir; ZDV,
zidovudine; 3TC, lamivudine; ddI, didanosine; d4T, stavudine. Reproduced with permission of Thomas Land Publishers from Bartlett et al.;
63 permission
conveyed through Copyright Clearance Center, Inc.
Review
917stabilized on a conventional HAART regimen (n¼308) to ﬁxed-
dose efavirenz/emtricitabine/tenofovir.
72 Most of the patients
(87%) were treated with efavirenz or a boosted PI, plus two NRTIs.
At 48 weeks, the rates of virological suppression with efavirenz/
emtricitabine/tenofovir were non-inferior to those with the baseline
regimen: respectively, 87% versus 85% had a VL of ,50 copies/
mL and 89% versus 88% of patients had a VL of ,200 copies/mL.
Among patients randomized to efavirenz/emtricitabine/tenofovir,
91% indicated a preference for this single-pill regimen.
Other data in treatment-experienced patients
Observational studies using the French Hospital HIV database
have evaluated the efﬁcacy of efavirenz-based regimens in patients
who were stabilized or failing on their ﬁrst PI-based regimens. In
patients with an undetectable VL on their ﬁrst PI regimen
(n¼2462), the 12 month rates of virological rebound were 6.8%,
13.7% and 12.3% in patients switched to regimens based on efa-
virenz, nevirapine and abacavir, respectively.
73 Compared with a
switch to efavirenz, there were signiﬁcant adjusted risks associated
with a switch to nevirapine (HR 1.53; 95% CI 1.21–1.94) or aba-
cavir (HR 1.53; 95% CI 1.12–2.08). Similarly, in patients with
detectable VL switched from an initial PI regimen (n¼1140),
12 month probabilities of virological suppression were 73.6%,
53.9% and 66.1% among patients whose treatment was switched
to efavirenz-, nevirapine- and abacavir-based HAART, respect-
ively.
74 Compared with patients switched to efavirenz, those
switched to nevirapine were more likely to experience treatment
failure (HR 0.63; 95% CI 0.54–0.74), while those switched to aba-
cavir showed a trend for increased risk of failure (HR 0.84; 95%
CI 0.68–1.04). The incidence of new AIDS-deﬁning events did
not differ signiﬁcantly across the groups.
Other studies have not shown differences in outcome
between efavirenz- and nevirapine-treated patients. In the NEFA
trial, 460 patients who were taking at least one PI combined
with two NRTIs and had stable virological suppression were ran-
domized to switch from the PI to nevirapine, efavirenz or abaca-
vir.
75 At 12 months the likelihood of reaching the primary
endpoint (death, progression to AIDS or an increase in HIV-1
RNA levels to  200 copies/mL) was 10% in the nevirapine
group, 6% in the efavirenz group and 13% in the abacavir group
(P¼0.10). The increases in CD4 cell count were similar in the
three groups.
75 At 3 year follow-up, the probability of virologi-
cal failure was similar in the efavirenz and nevirapine arms, but
higher in the abacavir arm.
76 Retrospective, observational
studies are vulnerable to selection bias and the conclusions
drawn from the French HIV database have been questioned.
77
The EuroSIDA observational study speciﬁcally compared vir-
ological outcome and genotypic resistance proﬁles in 759 patients
starting NNRTI-based regimens, 87% of whom had received pre-
vious antiretrovirals.
78 Overall, 74% of nevirapine recipients and
45% of efavirenz recipients experienced virological failure after
treatment initiation (P,0.001). After adjusting for confounding
factors, the HR for virological failure with efavirenz versus nevir-
apine was 0.50 (95% CI 0.39–0.65; P,0.001).
Thus, controlled clinical trials suggest that efavirenz provides
similar virological outcomes to nevirapine in patients with
experience of other antiretroviral drug classes. Some observa-
tional studies suggest superior outcomes with efavirenz but the
limitations of such studies (e.g. the absence of randomization)
should be kept in mind.
HIV subtypes
NNRTIs are highly selective for HIV-1 and do not inhibit
HIV-2. Efavirenz treatment has predominantly been studied in
patients with HIV-1 subtype B, the most prevalent form in
developed countries.
79 However, almost 90% of people infected
with HIV worldwide do not carry subtype B virus;
80 globally
50% are infected with subtype C.
81 Studies have shown that sub-
types B and C exhibit similar virological responses to efavir-
enz.
80,82,83 Studies on the differences between subtypes B and C
relating to genetic variations at NNRTI resistance-associated
positions have shown that mutation at positions such as V106M
and A98S is more common for patients with subtype C than
B.
82,83 However, Soares et al.
80 have reported that there is no
difference in the accumulation of NNRTI resistance mutations
between subtypes B and C.
Safety and tolerability
Efavirenz has been generally well tolerated in clinical trials.
According to the systematic review by Bartlett et al.,
63 4%–
16% of patients treated with efavirenz plus two NRTIs discon-
tinued treatment due to adverse events; the NRTI combinations
of lamivudine plus zidovudine or abacavir were associated with
the higher end of this range.
The most notable adverse events associated with efavirenz
are rash and central nervous system (CNS) symptoms. Rash is
common, but led to discontinuation in ,2% of patients and was
severe in ,1%.
84 When efavirenz and nevirapine were directly
compared (each plus lamivudine and stavudine) discontinuations
due to adverse events or HIV events occurred in 15.8% of
patients treated with efavirenz and 24.1% of patients treated
with nevirapine once daily (P¼0.011).
27 The difference
between the groups in adverse event-related discontinuations
was mainly due to a greater incidence of rash and hepatobiliary
toxicity with nevirapine.
27 In the FIRST study, grade 4 events
were approximately half as common with efavirenz as with
nevirapine (5.4 versus 10.2/100 person-years; P¼0.02).
28
CNS or neuropsychiatric disturbances have been reported in
 25%270% of patients receiving efavirenz.
84–88 Symptoms
include dizziness, headache, confusion, impaired concentration,
agitation, amnesia, psychotic symptoms, sleep abnormalities,
abnormal dreams and insomnia. These symptoms usually arise
within the ﬁrst few days of treatment and lead to early discon-
tinuation of efavirenz in  4%210% of patients, although some
investigators have reported higher discontinuation rates.
89 The
prevalence of most neuropsychiatric symptoms declines within a
few weeks if therapy is continued.
84,85,87,88,90 In a substudy of
the ACTG A5095 study, measures of neuropsychological per-
formance revealed no signiﬁcant difference between patients
who did and did not receive efavirenz.
91 While efavirenz recipi-
ents experienced more neurological symptoms at week 1
(P,0.001), this was not the case at week 4, 12 or 24. Patients
switched from another HAART regimen to efavirenz-based
therapy in Study AI266073 showed an initial increase in light-
headedness and dizziness, but these effects subsequently
reduced to baseline levels.
92
In a minority of patients, neuropsychiatric disturbances
persist for several months or longer,
89,90 or appear for the ﬁrst
time after several months of treatment with efavirenz.
93 CNS
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918side-effects are an important risk factor for failure of therapy
and for ‘blips’ in the HIV RNA level.
93
The mechanism of neuropsychiatric disturbances is not fully
understood. They may be partly related to previous psychiatric
disturbances or to neuropathic effects of HIV itself.
89 Studies in
animals have suggested that the effects of efavirenz on cytokines
may play a role in depression associated with efavirenz.
90 Sleep
disturbances may play a role in the development of neuropsy-
chiatric symptoms.
89 Neuropsychiatric disturbances appear to be
more common in African American patients than in European
American or Hispanic patients. This may be a consequence of a
higher prevalence of the CYP2B6 T/T genotype, resulting in
slower metabolism of efavirenz and higher plasma exposure.
16
Other studies have also given some (but not conclusive) evi-
dence that a higher plasma level of efavirenz increases the risk
of these problems.
86,89,90 Plasma monitoring may be considered
in patients with persistent symptoms. Nevirapine does not
appear to be associated with a high level of neuropsychiatric
events and it should be considered in patients at a high risk of
these symptoms.
27,86
Efavirenz-containing regimens may modestly increase plasma
lipid levels compared with a triple NRTI regimen.
94 The ACTG
A5142 study showed no signiﬁcant difference in the incidence
of grade 3–4 elevations in low-density lipoprotein-cholesterol
with efavirenz versus boosted lopinavir.
25 However, grade 3–4
increases in triglyceride levels were signiﬁcantly less common
with efavirenz (2%) than with boosted lopinavir (6%; P,0.05)
or efavirenz plus boosted lopinavir (14%; P,0.05). Other
head-to-head comparisons of these agents have also shown a
lesser effect of efavirenz on triglycerides.
26 These ﬁndings also
correspond with evidence that patients switched from PI-based
to efavirenz-based therapy show signiﬁcant improvements in tri-
glyceride and high-density lipoprotein levels.
72,95 Overall, efavir-
enz appears to have generally neutral effects on lipids, but this
depends to a large extent on the accompanying NRTIs.
96
Lipodystrophy can occur in patients receiving efavirenz-based
HAART. It may result partly from effects on adipocytes including
inhibition of lipogenesis and differentiation.
97,98 Some in vitro
studies have indicated that in contrast to efavirenz, nevirapine
does not inhibit lipogenesis.
98 Lipodystrophy is more common
when thymidine analogues, particularly stavudine, are included in
the NRTI backbone.
96 In the GS903 study, treatment-naive
patients were randomized to receive stavudine or tenofovir in
addition to efavirenz plus lamivudine.
34 Through 144 weeks,
investigator-reported lipodystrophy was signiﬁcantly less
common with tenofovir than with stavudine (3% versus 19% of
patients). Limb fat increased from year 2 to year 7 in patients ran-
domized to tenofovir during the extension phase of this study
59,60
and in patients who switched from stavudine to tenofovir at
144 weeks.
61 In GS934, treatment-naive patients were randomized
to receive efavirenz in combination with zidovudine/lamivudine
or tenofovir plus emtricitabine.
37,62 Limb fat was signiﬁcantly
(P,0.001) greater in the tenofovir plus emtricitabine arm.
Similarly, efavirenz recipients switched from ﬁxed-dose zidovu-
dine/lamivudine to ﬁxed-dose tenofovir/emtricitabine in the
SWEET study showed signiﬁcant (P¼0.025) increases in limb fat
compared with those who were not switched.
99
In the A5005S trial, patients were randomized to receive
efavirenz, nelﬁnavir or both, combined with zidovudine plus
lamivudine or didanosine plus stavudine.
100 At 144 weeks,
zidovudine plus lamivudine was superior to didanosine plus
stavudine with respect to limb fat loss, and the presence of nelﬁ-
navir (with or without efavirenz) was associated with additional
loss compared with efavirenz. In a 48 week study, efavirenz and
atazanavir (each added to zidovudine plus lamivudine) were
associated with similar increases in limb fat in treatment-naive
patients.
101 In the ACTG 5142 study, the incidence of lipoatro-
phy (deﬁned as .20% loss of limb fat) was 32% with efavirenz,
17% with lopinavir and 9% with efavirenz plus lopinavir (the
NRTI-sparing arm).
102 This result is difﬁcult to interpret
because the deﬁnition of lipoatrophy differs from that in other
studies and the choice of NNRTI backbone (lamivudine in all
patients with the addition of tenofovir, stavudine or zidovudine
at the investigators’ discretion) was not randomized. One study
showed that patients switching from a PI- to an efavirenz-based
HAART regimen did not exhibit changes in fat distribution.
103
A recent review concluded that efavirenz may produce a modest
gain in limb fat that is greater than that with nelﬁnavir, similar
to that with atazanavir and less than that with lopinavir.
96
Lipodystrophy associated with NRTIs is believed to occur
through mitochondrial toxicity. NRTIs can alter mitochondrial
function by inhibiting mitochondrial DNA polymerase g—the
enzyme responsible for replication of mitochondrial DNA.
104,105
This leads to reduced energy production and cellular damage,
resulting ultimately in lipodystrophy.
While exposure to HAART increases the risk of myocardial
infarction,
106 this appears to be due to PIs and not to NNRTIs.
107
Renal toxicity has been reported, albeit rarely, with tenofovir
administration.
108 Although small differences in glomerular ﬁl-
tration rate have occurred over time when tenofovir was combined
with efavirenz over 144 weeks in HAART-naive patients, no clini-
cally relevant renal disease or adverse events were observed.
109
Use of efavirenz in special patient populations
Recent statistics from the Antiretroviral Pregnancy Registry
showed no increase in the risk of overall birth defects associated
with drugs having sufﬁcient reports of ﬁrst-trimester exposure to
detect at least a 2-fold increase in risk.
110 Despite these obser-
vations, efavirenz should not be used in pregnant women unless
there are no other appropriate treatment options, and pregnancy
should be avoided in women receiving efavirenz.
9
Generally, guidelines do not make speciﬁc recommendations
for the selection of therapy in late-presenting HIV-infected
patients, i.e. those with low CD4 cell counts or high VL. Several
studies have demonstrated that efavirenz is similarly effective
regardless of the baseline CD4 count. In DMP 266-006, efavir-
enz (plus zidovudine and lamivudine) showed virological
response rates in both patients with CD4 counts ,100 cells/mm
3
and those with counts of  100 cells/mm
3.
23 In GS934,
efavirenz-containing regimens gave similar virological responses
in the overall population and in patients with baseline CD4 cell
counts ,200 cells/mm
3 or ,50 cells/mm
3.
111
Clinical trials have demonstrated that a regimen of efavirenz
plus two NRTIs has similar efﬁcacy in patients with a VL of
.100000 copies/mL or ,100000 copies/mL.
30,30–32,35 Similarly,
a post hoc analysis of ACTG 5095 revealed that rates of virological
failure following 3 years of treatment with efavirenz plus zidovu-
dine and lamivudine were not signiﬁcantly affected by baseline
VL (even up to  300000 copies/mL) or CD4 cell counts (down to
,50 cells/mm
3).
47
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919In the ACTG A5142 study, efavirenz-based therapy was
associated with a signiﬁcantly longer time to virological failure
than lopinavir-based therapy (P¼0.01) in patients with a VL of
 100000 copies/mL.
25 In a prospective, open-label study in
patients with baseline CD4 counts of ,200 cells/mm
3, efavirenz
was signiﬁcantly more effective than boosted lopinavir
(P¼0.0141) in terms of the proportion of patients who reached
aV Lo f,50 copies/mL at 48 weeks (Table 1).
26 Efavirenz
showed most beneﬁt over boosted lopinavir in patients with a
baseline CD4 count of  50 cells/mm
3 (79% versus 49% with a
VL of ,50 copies/mL; P¼0.012). Immune reconstitution was
similar between the groups. These results suggest that efavirenz
may be preferable to boosted lopinavir for initial therapy in
patients with advanced disease.
In the USA, the recommended therapy for children with HIV
depends on age, symptoms and immune status.
112 Efavirenz
(plus two NRTIs) is a recommended agent for the treatment of
children aged .3 years and weighing .10 kg; it is not rec-
ommended for children ,3 years of age or those who cannot
swallow capsules (efavirenz being available only in tablet or
capsule form in the USA).
Hepatitis B/C co-infection
Patients with HIV co-infected with hepatitis B virus (HBV) or
hepatitis C virus (HCV) have a signiﬁcantly worse prognosis than
those infected with HIV alone, and guidelines now recommend
early treatment of both conditions.
3,4 The choice between a PI- or
NNRTI-based regimen is determined using similar criteria to
those for patients without HBV/HCV co-infection. In patients
with HBV co-infection the NRTI backbone should include teno-
fovir or tenofovir plus lamivudine or emtricitabine because these
agents have activity against both HIV and HBV.
3,4 All antiretro-
viral agents have the potential for hepatotoxicity, which is
increased in the presence of HBV/HCV co-infection. Increased
hepatotoxicity, including elevated liver enzymes, has been seen
in patients co-infected with HBV/HCV (particularly HCV)
receiving efavirenz-based regimens.
113–116 It has been postulated
that HBV/HCV co-infection results in higher exposure to efavir-
enz, leading to the hepatic side-effects observed. However, recent
studies in patients with HIV have found no signiﬁcant differences
in efavirenz plasma levels between those with and without HBV/
HCV co-infection.
117,118 The cause of the increased risk of liver
toxicity remains to be determined. One study suggested that
nevirapine was associated with increased progression of liver
ﬁbrosis in patients co-infected with HCV,
119 but a more recent
investigation found that exposure to NNRTIs was associated with
reduction of ﬁbrosis and that this effect was more consistent with
nevirapine than with efavirenz.
120 Overall, the results suggest that
NNRTIs have an important role in the management of HBV/
HCV co-infected patients, with vigilant monitoring of hepatic
function. The data are insufﬁcient to indicate whether efavirenz
or nevirapine should be preferred.
Resistance
Resistance and drug class
Despite high levels of treatment success, resistance to efavirenz
can develop. Efavirenz resistance mutations developed in
6%–8% of patients treated with efavirenz plus two NRTIs for
2–3 years, with the K103N reverse transcriptase mutation being
by far the most common single mutation.
62,121 In the FIRST
study, efavirenz was associated with a signiﬁcantly lower rate of
virological failure in conjunction with NNRTI resistance (12.9
versus 20.6 person-years; P¼0.05) or any type of antiretroviral
resistance (13.3 versus 22.7/100 person-years; P¼0.02), com-
pared with nevirapine.
28 At the time of virological failure, rates
of resistance in the observational EuroSIDA study were similar
for efavirenz and nevirapine.
78
In ACTG A5142, resistance mutations were present in 48%
of efavirenz-treated patients with virological failure and an avail-
able genotype compared with 21% of those treated with boosted
lopinavir (P¼0.002).
25 Efavirenz was also associated with more
mutations associated with resistance to two drug classes and
more K65R mutations than boosted lopinavir. However, there
was no signiﬁcant difference between efavirenz- and lopinavir-
based therapy in the proportions of patients with virological
failure and at least one resistance mutation (9% versus 6%,
respectively).
Drug interactions
Knowledge of drug–drug interactions enables efavirenz-treated
patients with HIV to undergo therapy for other conditions while
maintaining viral suppression. Efavirenz is an inducer of cyto-
chrome P (CYP)3A4 and an inhibitor of some CYP450 isoen-
zymes including CYP3A4, and compounds that are substrates of
CYP3A4 may have decreased plasma concentrations when
co-administered with efavirenz. Patients co-infected with HIV
and Mycobacterium tuberculosis are an important subpopulation
and interactions occur between efavirenz and rifampicin and rifa-
butin, antibiotics used for the treatment of tuberculosis.
122
Co-administration of rifampicin and efavirenz results in decreased
efavirenz exposure and it is advised that the efavirenz dose should
be increased from 600 to 800 mg once daily when taken with
rifampicin.
84,123 Co-administration of rifabutin with efavirenz
results in reduced rifabutin exposure, and the daily dose of rifabu-
tin should be increased by 50% when administered with efavir-
enz,
84,124 while twice-weekly doses should be doubled. Caution
should be exercised when prescribing efavirenz for patients who
also need treatment for malaria, for example amodiaquine is con-
traindicated as it results in elevations of liver transaminases.
125
Several antimalarial drugs are metabolized by CYP3A4, e.g. halo-
fantrine, lumefantrine, the artemisinins and quinine, and
co-administration with efavirenz can result in increased/decreased
exposure to these drugs. Another subpopulation of patients with
HIV affected by efavirenz drug–drug interactions are those with
opioid dependence. Methadone concentrations are reduced when
co-administered with efavirenz, which leads to patients reporting
opioid withdrawal. An alternative drug for the treatment of opioid
dependence is buprenorphine. Buprenorphine has a pharmacoki-
netic but not a pharmacodynamic interaction with efavirenz, and
consequently co-administration with efavirenz does not result in
opioid withdrawal.
126,127
Lipid-lowering agents are commonly used in patients with
HIV to counteract metabolic disorders associated with HAART.
Efavirenz may interact with hydroxymethylglutaryl coenzyme
A (HMG-CoA) reductase inhibitors, such as atorvastatin,
pravastatin and simvastatin, that are metabolized primarily via
Review
920CYP3A4. Co-administration of efavirenz results in decreased
exposure to these agents, thus dosage adjustments may be
required.
128
Herbal preparations containing St John’s wort (Hypericum
perforatum) should not be used while taking efavirenz due to
the risk of decreased plasma concentrations and thus reduced
clinical effects of efavirenz.
84 Efavirenz must also not be
co-administered
84 with the antihistamines terfenadine and astem-
izole, the gastrointestinal agent cisapride, the sedatives midazo-
lam
129 and triazolam, the antipsychotic pimozide, the
arrhythmia drug bepridil or ergot alkaloids (e.g. ergotamine,
dihydroergotamine, ergonovine and methylergonovine) used as
antimigraine agents.
84 These agents compete with efavirenz for
CYP3A4, which could result in inhibition of metabolism and
create the potential for serious and/or life-threatening events
such as cardiac arrhythmias, prolonged sedation or respiratory
depression.
84 Efavirenz has also been shown to interact with the
ethinylestradiol component of oral contraceptives, with the con-
centration of ethinylestradiol increasing when co-administered
with efavirenz.
130 As the clinical signiﬁcance of this effect is
unknown, a reliable barrier method of contraception should be
used by patients receiving efavirenz in addition to oral
contraceptives.
84
Co-administration of efavirenz with other HAART agents
including PIs, boosted PIs and NRTIs is generally acceptable.
Exceptions are: boosted atazanavir,
131 which is not rec-
ommended; boosted lopinavir, for which dose increases are
recommended;
132 and low-dose ritonavir, which may lead to an
increased incidence of efavirenz-associated adverse events.
84,133
Implications of genotype
Efavirenz is principally metabolized by CYP2B6 and the
516G.T single nucleotide polymorphism is associated with
elevated efavirenz levels.
13 The TT genotype is more common
in black and Hispanic than white populations
12 and may be a
challenge in regions with a high prevalence of tuberculosis, as
efavirenz levels are increased in such patients receiving conco-
mitant rifampicin.
134 It has been reported that in patients with
the TT genotype, reduction of the efavirenz dose can maintain
virological suppression and alleviate CNS symptoms.
17 Patients
with the 983T.C polymorphism at position CYP2B6 also have
increased levels of efavirenz.
135
Resistance and future NNRTI therapy
The introduction of new NNRTIs (e.g. etravirine) necessitates a
consideration of how the selection of efavirenz-resistant mutants
might affect subsequent therapy with this drug class. A recent
genotypic analysis of 1586 HIV isolates with NNRTI resistance
mutations revealed that 8.2% had three or more mutations
associated with efavirenz resistance (e.g. G190A, Y181C and
K101E) while only 1.1% had four or more such mutations.
136
Mutational patterns associated with intermediate efavirenz resist-
ance occurred in 26.2% of the samples, while high-degree resist-
ance occurred in 4.9%. A separate analysis of 248 HIV isolates
from patients on stable NNRTI therapy in Italy revealed that
35.5% carried one efavirenz resistance mutation, 21.4% had two
mutations and 4.8% had three mutations.
137 Thus, while low to
intermediate efavirenz resistance may be relatively common in
NNRTI-resistant HIV, high-level efavirenz resistance appears
uncommon.
Efavirenz resistance mutations were signiﬁcantly more
common in stably treated patients receiving nevirapine than for
efavirenz (OR 2.73; 95% CI 1.62–4.62; P,0.001).
137 The prin-
cipal mutation selected by efavirenz—K103M—does not confer
resistance to efavirenz, while the primary mutation selected
during nevirapine therapy (Y181C) does confer efavirenz resist-
ance.
138 These data suggest that efavirenz is more likely to be
effective in patients previously treated with efavirenz than with
nevirapine.
In the DUET-1 and DUET-2 studies, etravirine showed efﬁ-
cacy versus placebo when used together with darunavir, NRTIs
and optional enfuvirtide, after the failure of antiretroviral
therapy in patients with genotypic evidence of resistance to cur-
rently available NNRTIs and PIs.
139,140 However, other data
indicate that a PI may be more effective than etravirine in
PI-naive patients after failure of an NNRTI-based regimen.
141
Adherence
Adherence is a major determinant of virological failure and may
lead to the emergence of resistance in patients with HIV, but the
relationships between resistance development, rebound and
adherence differ between antiretroviral drug classes.
142,143 A
large prospective study examined the rates of virological
rebound, resistance mutations and adherence in 1133 patients
with undetectable VL at baseline during treatment with HAART
based on NNRTIs (efavirenz 59% and nevirapine 41%) or PIs.
66
The rate of rebound (VL.50 copies/mL) was .10% in patients
treated with PIs (14.7%) or boosted PIs (11.7%) at an adherence
level of 76%295%, and  30%–50% at the lowest adherence
rates (,55%). For NNRTIs, adherence of ,55% was needed to
observe a similar rebound rate (17.6%) (Figure 4).
66 By contrast,
resistance selection decreased with increasing adherence for
NNRTIs, while the converse was true for unboosted PIs. The
risk of selecting NNRTI resistance mutations was estimated to
be 4.9% in NNRTI recipients at adherence rates of ,75% and
4.2% in single-PI recipients with .95% adherence. Boosted
PI-treated patients showed an intermediate pattern and a lower
level of resistance risk (1.3% resistance for adherence of 75%–
95%).
66 In the HOMER cohort study (n¼1634), the risk of viro-
logical breakthrough (deﬁned as two consecutive measurements
of VL .1000 copies/mL) was strongly associated with ,95%
adherence to the PI (HR 1.66; 95% CI 1.38–2.01) and NNRTI
(HR 1.47; 95% CI 1.01–2.14), but not the boosted PI (HR 1.05;
95% CI 0.46–2.42) treatments.
144 A smaller REACH cohort
study (n¼268) examining viral suppression (VL,50 copies/mL)
found that NNRTI- and boosted PI-based regimens were
comparable and better than PI regimens at achieving viral
suppression at levels of adherence of ,95%.
145
A recent study involving 1191 patients initiating HAART
found that those with ,95% adherence to NNRTIs were signiﬁ-
cantly more likely to accumulate resistance mutations than those
with  95% adherence (HR 7.0; 95% CI 3.4–14.5; P¼0.0001),
while adherence rates had little effect on resistance for PIs and
NRTIs.
146 Previously, Bangsberg et al.
147 compared the preva-
lence of resistance mutations according to the adherence levels
in patients (n¼108) stably treated with NNRTIs (35% efavirenz
and 65% nevirapine) or PIs. NNRTI-treated patients were more
Review
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PI-treated patients (50% versus 22%, respectively; P¼0.005).
Higher levels of adherence were signiﬁcantly associated with
improved viral suppression with each class. At low adherence
levels (0%–48%), NNRTI resistance was more common than PI
resistance (69% versus 23%; P¼0.01). The frequency of
NNRTI resistance decreased as adherence increased, from 69%
in patients with 0%–48% adherence to 13% in those with
95%–100% adherence (P¼0.01). On multivariate analysis, each
10% improvement in adherence decreased the risk of NNRTI
resistance by 25% (P¼0.04). In contrast, the risk of PI resist-
ance increased by 41% (P¼0.03) with each 10% improvement
in adherence.
A prospective study of 543 virologically suppressed patients
found that the rate of self-reported adherence was slightly, but
signiﬁcantly, higher with NNRTI-based HAART than with
PI-based HAART (mean 93.6% versus 89.9%, respectively;
P¼0.018).
148 PI recipients with a self-reported adherence rate
of  85% had a virological failure rate of .20% over 6 months.
In contrast, virological failure rates in NNRTI recipients (of
whom 57% were taking efavirenz and 43% were taking nevira-
pine) exceeded 10% only when their adherence rate was  75%.
In patients with an adherence rate of .75%, virological failure
was less likely with NNRTIs than with PIs.
These differences between classes have been explained by
differences in the relative replicative ﬁtness of resistant viruses
(versus susceptible strains) in the presence of the drugs
147 as
well as the pharmacokinetic and pharmacodynamic differences
between the classes.
66 Other recent data suggest that the spacing
of missed doses is also important to resistance risk with
NNRTIs. Thus, in patients with low-to-moderate adherence
(,80%), the duration of sustained treatment interruption
was linked to virological rebound, while average adherence
(i.e. interspersed missed doses as a percentage of total doses)
was not.
149
One of the most important factors in the level of adherence is
the number of pills that must be taken per day,
150 with patients pre-
ferring once-daily regimens.
68,72,151 Preliminary patient-reported
outcomes in the ADONE study suggested that patients found a
single-dose efavirenz/tenofovir/emtricitabine treatment highly
preferable in terms of simplicity, convenience, tolerability and
potency, and more patients reported being without HIV-related
symptoms.
151
Quality of life
A substudy of the 2NN trial reported that efavirenz or nevirapine
improved health-related quality of life in treatment-naive
patients.
152 In the randomized INITO trial, efavirenz-based or
nelﬁnavir-based therapy improved physical and mental health
scores during 3 year follow-up.
153 In the VESD study over
two-thirds of patients receiving once-daily efavirenz/didanosine/
lamivudine considered their quality of life ‘good’ or ‘very good’
at 6 and 12 months.
154 In the AI266073 study, patients who
switched to a single-dose efavirenz/emtricitabine/tenofovir treat-
ment reported improvements in HIV-related symptoms such as
diarrhoea, bloating, pain, gas, change in the way their body
looked and problems having sex, although they also experienced
transient worsening of CNS symptoms at week 4.
66,92 Other
studies have also reported improved treatment satisfaction after
switching to the ﬁxed-dose regimen.
70
Neuropsychiatric symptoms with efavirenz impair quality of
life in some patients, especially at the start of therapy.
86,89,90
This is important because lower quality of life during treatment
with efavirenz is a predictor of virological failure.
155 Depression
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Figure 4. Proportions of patients experiencing virological rebound according to their reported adherence rate. Total and type of HAART adjusted analysis.
Total HAART, column 1; single PI, column 2; boosted PI, column 3; NNRTI, column 4. Reproduced with permission of Thomas Land Publishers from
Maggiolo et al.;
66 permission conveyed through Copyright Clearance Center, Inc.
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922is important because it is commonly overlooked in patients with
HIV infection.
156 However, one report suggests that if patients
are able to continue long-term efavirenz-based therapy, their
quality of life can be good despite persisting neuropsychiatric
symptoms.
157
Cost-effectiveness
Few pharmacoeconomic studies have compared recommended
options for HIV treatment. Basu et al.
158 used pooled data from
clinical trials to compare the costs of reaching and maintaining
an undetectable VL in HAART-naive patients using each of the
nine NNRTI- and PI-based regimens recommended in 2005.
Efavirenz- and boosted lopinavir-based regimens were the most
effective in terms of virological suppression rates. Efavirenz was
consistently the third agent associated with the lowest cost per
patient with undetectable VL across time periods ranging from
30 to 96 weeks.
More recently, a study in the UK compared the cost-
effectiveness of various initial HAART regimens, taking into
account the annual costs of inpatient and outpatient visits, day
ward visits, HAART, other drugs, tests and procedures, together
with effectiveness measured as time to treatment failure.
159
First-line use of an NNRTI plus two NRTIs was calculated to be
cost-effective or cost-saving compared with boosted PI-containing
regimens.
Conclusions
Numerous clinical trials performed over the last 10 years have
established the effectiveness of efavirenz-based HAART in the
initial treatment of HIV-infected individuals. Efavirenz has
shown potent and durable virological suppression in this setting,
with efﬁcacy demonstrated over 7 years. Recent data also conﬁrm
that efavirenz is a cost-effective option for ﬁrst-line therapy.
The once-daily dosing schedule of efavirenz has enabled its
inclusion in the ﬁrst one-tablet once-a-day regimen alongside
two widely used NRTIs. The convenience of this regimen may
aid long-term adherence and perhaps increase the durability of
treatment responses. Several studies have shown that patients
stable on PI-based HAART requiring multiple daily doses and
pills can be switched to simpliﬁed efavirenz-based regimens
without loss of virological control. Efavirenz also retains a role
in the management of patients after failure of a ﬁrst-line
PI-based regimen.
Efavirenz is generally well tolerated during prolonged
therapy, although neuropsychiatric symptoms are common in the
ﬁrst few weeks of treatment and lead to discontinuation in a
relatively small proportion of patients. Efavirenz appears to be
generally neutral on lipids. Efavirenz-based regimens can be
associated with lipodystrophy but the use of newer NRTI back-
bones (e.g. tenofovir and emtricitabine) appears to reduce this
problem. The potential for resistance selection by efavirenz
underscores the need for high levels of treatment adherence.
Evidence suggests that efavirenz is unlikely to compromise the
efﬁcacy of the newer NNRTIs, such as etravirine.
In light of these features, efavirenz retains a key role in the
recommended HIV treatment strategies and is recommended as
the ﬁrst-line agent in some guidelines.
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